US generics tariffs more negotiation tactic than real threat: Biocon’s Kiran Mazumdar-Shaw
· livemint.com
The company, which is among the world’s top biosimilars manufacturers, remains in a wait-and-watch mode, while exploring partnerships for manufacturing in the US if required, Shaw said.
Jessica Jani
Jessica has been tracking the pharmaceutical, life sciences and healthcare sector for Mint since November 2024. Based in the country's financial c...